A Phase 1 Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Indonesia/05/05 (H5N1) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Young Adults With and Without Adjuvant 1.

Novavax5 sites in 1 country333 target enrollmentApril 2012

ConditionsInfluenza (Pandemic)

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Influenza (Pandemic)
Sponsor: Novavax
Enrollment: 333
Locations: 5
Primary Endpoint: Number of solicited and unsolicited adverse events in H5N1 VLP antigen dose groups delivering HA with/without Adjuvant 1.
Status: Completed
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the immunogenicity and safety profile of the Avian flu vaccine with and without adjuvant 1 in healthy, young adults. The study is divided down into Parts A1, A2 and B. Groups within each Part will receive two doses of the assigned test article on Study Days 0 and 21. There will be a Safety Monitoring Committee assessment following Day 7 for each part, prior to allowing vaccination of subjects in subsequent Parts of the study.

Registry

clinicaltrials.gov

Start Date

April 2012

End Date

August 2013

Last Updated

12 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Novavax

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Healthy adult male or female, ≥18 and ≤49 years of age,
•Willing and able to give informed consent prior to study enrollment,
•Able to comply with study requirements, and
•Women must have a negative urine pregnancy test prior to each vaccination; will be advised through the Informed Consent process to avoid becoming pregnant over the duration of the study, and must assert that they will employ an effective form of birth control for the duration of the study. Acceptable forms of birth control are: credible history of continuous abstinence from heterosexual activity or prior surgical sterilization, hormonal contraceptives (oral, injectable, implant, patch, ring), double-barrier contraceptives (condom or diaphragm, with spermicide), and intrauterine device (IUD).

Exclusion Criteria

•Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care. Asymptomatic conditions (e.g., hypertension, dyslipidemia) that are being managed medically and that are not associated with evidence of end-organ damage are not exclusionary provided they are clinically stable (defined as no unscheduled medical interventions or change in medications for cause within 3 months).
•Any history of jaundice, or of hepatic injury due to drug (prescription, OTC, or illicit) or alcohol use or viral hepatitis; or the presence of hepatitis B surface antigen or hepatitis C antibody at screening.
•Any grade 1 or higher (as based on the Toxicity Grading Scale \[TGS\]) abnormality in ALT, AST, alkaline phosphatase or total bilirubin levels.
•Any grade 2 or higher (as based on the TGS) vital sign or clinical laboratory abnormality not specified in criterion 3 above. Note that any abnormal vital sign may be repeated at the Investigator's discretion.
•Participation in research involving investigational product (drug / biologic / device) within 45 days before planned date of first vaccination.
•History of a serious reaction to prior influenza vaccination.
•History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza vaccine.
•Received any vaccine in the 4 weeks preceding the study vaccination; or any A/H5N1 avian influenza vaccine at any time.
•Any known or suspected immunosuppressive condition, acquired or congenital, including HIV infection as determined by history and/or physical examination.
•Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.

Outcomes

Primary Outcomes

Number of solicited and unsolicited adverse events in H5N1 VLP antigen dose groups delivering HA with/without Adjuvant 1.

Time Frame: Day 42

Secondary Outcomes

Measurement of HAI antibody seroconversion rates and GMT achieved by a constant H5N1 VLP antigen dose alone and in combination with Adjuvant 1.(Day 42)